[Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vir Biotechnology (VIR): A reporting group affiliated with SoftBank—SVF Endurance (Cayman) Limited—reported open‑market sales of Vir common stock under a Rule 10b5‑1 trading plan entered into on September 3, 2025. On 10/09/2025, it sold 249,060 shares at a weighted average price of $6.1428. On 10/10/2025, it sold 2,300 shares at a weighted average price of $6.0752.

Following these transactions, the filing shows beneficial ownership of 15,372,309 shares after the first sale and 15,370,009 shares after the second, held indirectly, with SVF Endurance as record holder and SB Investment Advisers (UK) Limited managing SoftBank Vision Fund (AIV M1) L.P. The reporting person is listed as a Director and 10% Owner.

Insights

Equity markets analyst

Planned insider sales by a 10% holder; neutral signal.

SVF Endurance (Cayman) Limited disclosed two small open‑market sales of VIR common stock executed under a pre‑set Rule 10b5‑1 plan. The trades were 249,060 shares at a weighted average of $6.1428 on 10/09/2025 and 2,300 shares at $6.0752 on 10/10/2025.

The filing lists post‑trade beneficial ownership of 15,372,309 shares after the first transaction and 15,370,009 after the second, held indirectly via SVF Endurance, with SB Investment Advisers (UK) Limited managing the fund entity. As these are plan‑driven sales by a Director and 10% Owner, they are commonly administrative.

Actual market impact depends on future trading activity disclosed in subsequent filings. The weighted‑average pricing and share counts are explicitly stated, and the plan adoption date anchors these as pre‑arranged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		S(1)		249,060	D	$6.1428(2)	15,372,309	I	See footnote(3)
Common Stock	10/10/2025		S(1)		2,300	D	$6.0752(4)	15,370,009	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SOFTBANK VISION FUND (AIV M1) L.P.

(Last) (First) (Middle)

1521 CONCORD PIKE

(Street)

WILMINGTON, DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SB INVESTMENT ADVISERS (UK) LTD

(Last) (First) (Middle)

69 GROSVENOR STREET

(Street)

LONDON, X0 W1K 3JP

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.9625 to $6.35. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.09. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director	10/14/2025
	SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel	10/14/2025
	SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did VIR’s reporting person disclose on Form 4?

Two open‑market sales of Vir Biotechnology common stock by SVF Endurance (Cayman) Limited under a Rule 10b5‑1 plan.

How many VIR shares were sold and on which dates?

249,060 shares on 10/09/2025 at a weighted average of $6.1428, and 2,300 shares on 10/10/2025 at a weighted average of $6.0752.

How many VIR shares does the reporting person beneficially own after the transactions?

15,372,309 shares after the 10/09/2025 sale and 15,370,009 shares after the 10/10/2025 sale.

Was the trading conducted under a Rule 10b5-1 plan?

Yes. The plan was entered into on September 3, 2025, and the reported sales were effected pursuant to that plan.

Who is the record holder of the reported VIR shares?

SVF Endurance (Cayman) Limited is the record holder; it is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P.

What is the reporting person’s relationship to VIR?

The reporting person is listed as a Director and 10% Owner.